RECRUITING

The Neurodevelopmental and Behavioral Phenotyping Screening Protocol

Talk to us

Conditions

Neurologic DisordersAutismNeurodegenerative DiseaseNeurobehavioral ManifestationDevelopmental DelayPediatricPervasive Developmental DisorderEarly DevelopmentHealthy Control SubjectsAutism Spectrum DisordersHealthy VolunteerHV

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this protocol is to allow for the careful evaluation of healthy volunteers and individuals with risk for psychiatric disorders or neurodevelopmental disorders, such as autism spectrum disorder for specific protocols at NIH....

Official Title

Neurodevelopmental and Behavioral Phenotyping Screening Protocol

Quick Facts

Study Start:2006-02-27
Study Completion:N/A
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT00271622

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:6 Weeks
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Subjects must be at least 6 weeks of age.
  2. * Subjects or their parents must be competent to comprehend the purpose of the screening process and to provide written informed consent. Parents/guardians will sign the consent form, and both minors and adults (depending on results of capacity assessment) will be asked to assent only if it is determined that they understand their role in the study.
  3. * Subjects must be willing to undergo an evaluation which may include a psychiatric interview; and medical, neurological, and laboratory examinations (as appropriate, such as renal and liver function tests, serum electrolytes, urinalysis, blood levels of psychotropic drugs, and urine drug screen for the presence of psychoactive drugs and drugs of abuse, as determined on a subject-to-subject basis).
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Margaret J Pekar
CONTACT
(301) 435-7962
pekarm@mail.nih.gov
Genalynne C Mooneyham, M.D.
CONTACT
(301) 435-6651
gena.mooneyham@nih.gov

Principal Investigator

Genalynne C Mooneyham, M.D.
PRINCIPAL_INVESTIGATOR
National Institute of Mental Health (NIMH)

Study Locations (Sites)

National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
United States

Collaborators and Investigators

Sponsor: National Institute of Mental Health (NIMH)

  • Genalynne C Mooneyham, M.D., PRINCIPAL_INVESTIGATOR, National Institute of Mental Health (NIMH)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2006-02-27
Study Completion DateN/A

Study Record Updates

Study Start Date2006-02-27
Study Completion DateN/A

Terms related to this study

Keywords Provided by Researchers

  • Developmental Delay
  • Pediatric
  • Pervasive Developmental Disorder
  • Early Development
  • Healthy Control Subjects
  • Autism Spectrum Disorders
  • Healthy Volunteer
  • HV

Additional Relevant MeSH Terms

  • Neurologic Disorders
  • Autism
  • Neurodegenerative Disease
  • Neurobehavioral Manifestation